Analyst Price Targets — CGON
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 7, 2026 2:07 pm | — | Truist Financial | $85.00 | $74.35 | TheFly | CG Oncology price target raised to $85 from $82 at Truist |
| July 29, 2026 10:49 am | Andres Maldonado | H.C. Wainwright | $100.00 | $72.62 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on CG Oncology (CGON) |
| May 14, 2026 1:18 pm | — | Truist Financial | $82.00 | $70.01 | TheFly | CG Oncology price target raised to $82 from $77 at Truist |
| May 11, 2026 1:29 pm | — | RBC Capital | $81.00 | $70.91 | TheFly | CG Oncology price target raised to $81 from $79 at RBC Capital |
| May 11, 2026 11:50 am | — | Wedbush | $80.00 | $69.62 | TheFly | CG Oncology price target raised to $80 from $77 at Wedbush |
| April 27, 2026 12:09 pm | — | RBC Capital | $79.00 | $69.42 | TheFly | CG Oncology price target raised to $79 from $73 at RBC Capital |
| March 26, 2026 1:03 pm | — | UBS | $90.00 | $66.67 | TheFly | CG Oncology price target raised to $90 from $60 at UBS |
| February 10, 2026 2:19 pm | — | Truist Financial | $75.00 | $53.39 | TheFly | CG Oncology price target raised to $75 from $66 at Truist |
| January 21, 2026 11:34 am | — | RBC Capital | $73.00 | $54.69 | TheFly | CG Oncology price target raised to $73 from $61 at RBC Capital |
| January 16, 2026 11:55 am | Kelsey Goodwin | Piper Sandler | $70.00 | $53.07 | TheFly | CG Oncology price target raised to $70 from $55 at Piper Sandler |
Latest News for CGON
Bond yields have the entire stock market on edge. The last thing most investors are thinking about is short squeezes, which means maybe they should be something contrarian trades have on their radar.
DALLAS, Sept. 02, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced that Arthur Kuan, Chairman, President & Chief Executive Officer, will participate in fireside chat presentations at the Cantor Fitzgerald and Morgan Stanley Global Healthcare Conferences in New York City this month. The details of the upcoming events are as follows:
NEW YORK, Aug. 19, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of CG Oncology, Inc. ( NASDAQ : CGON) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.
CG Oncology is advancing cretositimogene grenadenorepvec (cret) for NMIBC, showing strong efficacy and best-in-class safety versus competitors. Cret achieved a 75% anytime CR, 46% 12-month CR, and 42% 24-month CR in BOND-003 Cohort C, with no Grade 3+ adverse events. Rolling BLA for cret in HR BCG-unresponsive NMIBC is expected to complete in 4Q26, with multiple trial readouts in 2H26 and 2027.
California State Teachers Retirement System increased its stake in CG Oncology, Inc. (NASDAQ: CGON) by 23.6% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 51,499 shares of the company's stock after purchasing an additional 9,841 shares during the
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CGON.
U.S. House Trading
No House trades found for CGON.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.